Trazodone Use in Anorexia Nervosa: Clinical Recommendation
You should carefully reassess the continued use of trazodone in your patient with anorexia nervosa, particularly evaluating cardiac safety with an ECG and considering whether the medication is addressing a specific comorbid condition that justifies its continuation, as there is no evidence supporting antidepressant efficacy for core AN symptoms and significant safety concerns exist in this population.
Key Safety Concerns in AN Patients
The 2023 APA guidelines explicitly recommend obtaining an ECG in patients with restrictive eating disorders, especially those taking medications known to prolong QTc intervals 1. Trazodone carries risk for QT prolongation and cardiac arrhythmias 2, making this particularly relevant for your patient who has been on it for 3 years.
Critical Cardiac Monitoring Required:
- Obtain an ECG immediately if not done recently 1
- Check electrolytes, particularly potassium and magnesium 1
- Assess for orthostatic vital sign changes 1
- Monitor for irregular or fast heartbeat 2
Evidence Against Antidepressant Use in Acute AN
The evidence base is clear and consistent: antidepressants lack efficacy for core AN symptoms during acute treatment 3, 4. A Cochrane review found that placebo-controlled trials showed no evidence that antidepressants improved weight gain, eating disorder symptoms, or associated psychopathology 4. A 2018 review specifically states that SSRIs during acute treatment lack efficacy 3.
When Trazodone Might Be Justified
Trazodone continuation may be appropriate only if:
The patient is weight-restored (at appropriate percentage of ideal body weight)
Treating a specific comorbid condition such as:
- Persistent insomnia unresponsive to behavioral interventions
- Major depressive disorder that emerged independently of AN
- Severe anxiety disorder requiring pharmacotherapy
No cardiac contraindications exist (normal ECG, stable electrolytes)
Practical Decision Algorithm
Step 1: Determine current nutritional status
- If underweight/malnourished → Strong consideration for discontinuation due to altered pharmacokinetics 5 and lack of efficacy 3
- If weight-restored → Proceed to Step 2
Step 2: Cardiac safety assessment
- Obtain ECG and metabolic panel 1
- If QTc prolongation present → Discontinue trazodone 2
- If cardiac parameters normal → Proceed to Step 3
Step 3: Evaluate therapeutic indication
- Is trazodone treating a specific comorbid condition that has responded to treatment?
- If no clear benefit or indication → Taper and discontinue 2
- If clear benefit for comorbid condition → Continue with close monitoring
Critical Pitfalls to Avoid
Do not abruptly discontinue trazodone - the FDA label warns that sudden cessation can cause withdrawal symptoms including anxiety, agitation, and sleep problems 2. Taper gradually while monitoring.
Do not assume long-term use equals necessity - After 3 years, reassess whether the original indication still exists and whether benefits outweigh risks in the context of AN.
Do not overlook medication interactions - Malnutrition alters drug metabolism 5, potentially increasing trazodone levels and side effect risk even at stable doses.
Recommended Approach
The 2023 APA guidelines emphasize that eating disorder-focused psychotherapy is the primary treatment for AN 1, not medication. Your treatment plan should prioritize:
- Nutritional rehabilitation and weight restoration with individualized weekly weight gain goals 1
- Eating disorder-focused psychotherapy addressing fear of weight gain and body image 1
- Medication only for specific comorbid psychiatric conditions that persist after nutritional rehabilitation
Given the lack of evidence for antidepressant efficacy in AN 3, 4, 6, the cardiac risks in restrictive eating disorders 1, and trazodone's specific QT prolongation risk 2, a trial of gradual discontinuation is warranted unless there is a compelling, documented indication for continuation in a weight-restored patient with normal cardiac function.